Newly discovered protein could treat and prevent severe diabetic complications, finds study

Image
ANI
Last Updated : Apr 07 2019 | 2:20 PM IST

A new study has shown that a recently discovered protein called neuronostatin could give new ways to treat and prevent hypoglycaemia, which is sometimes deadly for people with diabetes.

The research was presented at the American Physiological Society's annual meeting during the 2019 Experimental Biology meeting.

People with diabetes who use insulin to control their blood sugar can experience a dangerous condition called hypoglycemia when blood sugar levels fall too low.

For people with diabetes, taking too much insulin can lead to low blood sugar, causing dizziness and sleepiness. Symptoms may progress to confusion, seizures, and loss of consciousness if blood sugar levels continue to fall.

Severe hypoglycemia can also increase the risk of more hypoglycemic episodes in the following days and leads to a decreased awareness of the symptoms that typically allow a person to sense falling blood sugar levels.

"There are very few options for preventing hypoglycemia or treating hypoglycemia unawareness other than avoiding low blood sugar as much as possible," said Stephen Grote, a researcher."Understanding what neuronostatin does and how it works will provide valuable information for preventing hypoglycemia and provide more complete knowledge into how the pancreas manages blood sugar normally," he added.

In previous work, Yosten's research group discovered neuronostatin. Their work has shown that the protein protects against hypoglycemia by causing the pancreas to release less insulin and make more glucagon, a hormone that helps regulate blood sugar levels.

In a new rat study, the researchers observed that neuronostatin injections caused an increase in blood sugar. They also examined human pancreas tissue and found that it released more neuronostatin when blood sugar levels were low and that neuronostatin increased even more with glucagon treatment.

The new research points to neuronostatin as a potential therapeutic target for the treatment and prevention of hypoglycemia in people with diabetes.

"Neuronostatin is a truly novel factor, and everything we find about it pushes our knowledge of its therapeutic potential just a bit further. We believe that studying neuronostatin could ultimately reveal a way to use it to help prevent and reverse vicious cycles of hypoglycemia by helping the body respond appropriately to the low blood sugar with more glucagon," said Grote.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 07 2019 | 1:59 PM IST

Next Story